Asthma is a highly prevalent chronic respiratory disease affecting 300 million people world‐
wide. A significant fraction of the cost and morbidity of asthma derives from acute care for …

Summary Background Omalizumab (Xolair®) is a recombinant humanized monoclonal anti‐
IgE antibody with proven efficacy in patients with moderate‐to‐severe and severe persistent …

The Second Edition of Asthma and COPD: Basic Mechanisms and Clinical Management
continues to provide a unique and authoritative comparison of asthma and COPD. Written …

Background Churg-Strauss syndrome (CSS) is a rare systemic vasculitis associated with
asthma, eosinophilia, sinusitis, and pulmonary infiltrates. CSS has been reported in …

Asthma is a chronic inflammatory disease of the airways in which immunoglobulin E (IgE)
plays a key role by activating a variety of inflammatory cells through interactions with FcɛRI …

Severe persistent asthma causes a substantial morbidity and mortality burden and is
frequently inadequately controlled despite intensive guideline-based therapy. Targeting …

Background: Anti‐IgE, omalizumab, inhibits the allergen response in patients with asthma.
This has not been directly related to changes in inflammatory conditions. We hypothesized …

Airway inflammation, airway remodeling and airway hyperresponsiveness are the
fundamental components of pathogenesis that lead to symptoms and lung function changes …

Background: Omalizumab is a monoclonal, humanized antibody specific for the region of IgE
that binds to the high affinity IgE receptor on basophils and mast cells. Subcutaneous …

This review summarizes selected articles appearing in 2008 in the Journal. Articles chosen
include those improving our understanding of mechanisms of allergic diseases by focusing …